Total Payments
$177,233
2024 Payments
$2,451
Companies
10
Transactions
100
Payment Breakdown by Category
Research$170,714 (96.3%)
Travel$4,640 (2.6%)
Food & Beverage$1,879 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $170,714 | 40 | 96.3% |
| Travel and Lodging | $4,640 | 23 | 2.6% |
| Food and Beverage | $1,879 | 37 | 1.1% |
Payments by Type
Research
$170,714
40 transactions
General
$6,519
60 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $162,257 | 14 | $0 (2023) |
| Eli Lilly and Company | $5,877 | 5 | $0 (2023) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,820 | 10 | $0 (2020) |
| EISAI INC. | $1,784 | 26 | $0 (2022) |
| Sage Therapeutics, Inc. | $1,745 | 11 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,663 | 17 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $787.28 | 3 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $760.01 | 11 | $0 (2023) |
| Grifols Biologicals LLC | $455.24 | 2 | $0 (2019) |
| Gilead Sciences, Inc. | $84.98 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,451 | 20 | E.R. Squibb & Sons, L.L.C. ($1,663) |
| 2023 | $75,927 | 31 | Janssen Research & Development, LLC ($72,965) |
| 2022 | $90,760 | 18 | Janssen Research & Development, LLC ($89,291) |
| 2021 | $289.35 | 1 | Eli Lilly and Company ($289.35) |
| 2020 | $1,457 | 5 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,457) |
| 2019 | $1,629 | 15 | Eisai Inc. ($985.77) |
| 2018 | $647.48 | 8 | Eisai Inc. ($473.03) |
| 2017 | $4,072 | 2 | Eli Lilly and Company ($4,072) |
All Payment Transactions
100 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $389.21 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $225.94 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $225.94 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $155.86 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $140.71 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $75.00 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $75.00 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $70.00 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $70.00 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $40.66 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $32.99 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.73 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.73 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.73 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.73 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $25.87 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $25.28 | General |
| 10/02/2024 | IDORSIA PHARMACEUTICALS US INC | Cenerimod | Travel and Lodging | Cash or cash equivalent | $74.67 | General |
| 10/02/2024 | IDORSIA PHARMACEUTICALS US INC | Cenerimod | Food and Beverage | In-kind items and services | $35.00 | General |
| 09/26/2024 | IDORSIA PHARMACEUTICALS US INC | Cenerimod | Travel and Lodging | Cash or cash equivalent | $677.61 | General |
| 12/31/2023 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $22,377.50 | Research |
| Study: 42847922ALZ2001 | ||||||
| 12/31/2023 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $8,768.60 | Research |
| Study: 42847922ALZ2001 | ||||||
| 12/31/2023 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $2,473.90 | Research |
| Study: 42847922ALZ2001 | ||||||
| 09/30/2023 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $8,768.60 | Research |
| Study: 42847922ALZ2001 | ||||||
| 09/30/2023 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $4,270.90 | Research |
| Study: 42847922ALZ2001 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 42847922ALZ2001 | Janssen Research & Development, LLC | $162,257 | 14 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $3,420 | 1 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,457 | 5 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,433 | 2 |
| A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | Teva Pharmaceuticals USA, Inc. | $760.01 | 11 |
| A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | Eli Lilly and Company | $652.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $372.40 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $187.92 | 3 |
| A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE OPC34712 IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $174.45 | 2 |
About Dr. Michael Pfeffer, MD
Dr. Michael Pfeffer, MD is a Specialist healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467532093.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Pfeffer, MD has received a total of $177,233 in payments from pharmaceutical and medical device companies, with $2,451 received in 2024. These payments were reported across 100 transactions from 10 companies. The most common payment nature is "" ($170,714).
Ad
Practice Information
- Specialty Specialist
- Other Specialties Neurology
- Location Miami, FL
- Active Since 10/17/2006
- Last Updated 01/27/2016
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1467532093
Products in Payments
- REXULTI (Drug) $1,457
- Cenerimod $787.28
- Albutein (Biological) $455.24
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Miami
Dr. Orlando Puente, Md, MD
Specialist — Payments: $257,492
Specialist $257,492
Dr. Shyam Sathanandam, M.d, M.D
Specialist — Payments: $247,545
Specialist $247,545
Dr. Peter Weissman, Md, MD
Specialist — Payments: $229,129
Specialist $229,129
Dr. Miguel Flores, Md, MD
Specialist — Payments: $224,206
Specialist $224,206
Dr. Alejandro Badia, Md, MD
Specialist — Payments: $155,292
Specialist $155,292
Dr. Theodore Malinin
Specialist — Payments: $136,681
Specialist $136,681